High Prevalence of HER-2/neu and p53 Overexpression in Inflammatory Breast Cancer

Background Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Although the survival of patients with IBC has been greatly improved by the use of combined treatment modalities, women with IBC still have lower survival rates. We have summarized a single-center experience involving IBC patients. Our objectives are to clarify molecular alterations of HER- 2/neu and p53 in IBC and to investigate the prognostic factors.